{"id":49668,"date":"2022-10-17T08:01:38","date_gmt":"2022-10-17T06:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/"},"modified":"2022-10-17T08:01:38","modified_gmt":"2022-10-17T06:01:38","slug":"polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/","title":{"rendered":"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation<\/i>\n<\/li>\n<li>\n<i>Addition of late stage clinical and commercial-scale production is also planned<\/i>\n<\/li>\n<li>\n<i>Company to present on shielding lipid novel excipients for lipid nanoparticle (LNP) formulations at Lipid Nanoparticles Development Summit on October 20<sup>th<\/sup><\/i>\n<\/li>\n<\/ul>\n<p>VALENCIA, Spain &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211;Polypeptide Therapeutic Solutions (PTS), a leader in the design, development, and custom manufacturing of polyamino-acid based delivery systems for vaccines and therapeutics, today announced the company has changed its name to <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.curapath.com%2F&amp;esheet=52945034&amp;newsitemid=20221016005015&amp;lan=en-US&amp;anchor=Curapath&amp;index=1&amp;md5=aff6547c2afa473639c530eebc387e06\" rel=\"nofollow noopener\" shape=\"rect\">Curapath<\/a>. As part of Curapath\u2019s transformation, the company has expanded existing capabilities in development and production of novel functional lipid and polymer excipients and nanoparticle formulations.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/4\/Curapath_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/21\/Curapath_logo.jpg\"><\/a><\/p>\n<p>\n\u201cPTS was established ten years ago and since that time, our capabilities and services have continuously expanded to address the evolving drug delivery challenges of our clients, including the world\u2019s leading vaccine and therapeutic manufacturers,\u201d said Robert Shaw, Chief Executive Officer. \u201cOur new name, Curapath, reflects our broadened portfolio of services beyond polymers and represents our commitment to provide support throughout the journey of novel vaccines and therapeutics, from development to approval.\u201d\n<\/p>\n<p>\nThe expanded capabilities build upon the company\u2019s comprehensive portfolio of services which include development, formulation, analytical method development, GMP manufacturing, and fill and finish. Curapath is also adding manufacturing capacity to support late-stage and commercial-scale production of novel functional excipients and nanoparticles.\n<\/p>\n<p>\n\u201cOur vision is to enable biopharmaceutical innovators to overcome drug delivery and safety challenges, accelerate progress toward clinical milestones, and unlock the full value and potential of their advanced therapies and vaccines,\u201d said Vicent J. Nebot, PhD, Chief Technical Officer. \u201cWe do this by supporting customers in developing and manufacturing the most advanced polymer- and lipid-based delivery systems so that medicines and vaccines can safely target the right pathways and tissues to deliver the desired therapeutic effects. By expanding our capabilities in novel functional excipients and nanoparticle formulations, we stay at the forefront of innovative solutions for drug delivery and continue supporting the clinical development path of our clients.\u201d\n<\/p>\n<p>\nMembers of the Curapath technical team will be at the Lipid Nanoparticles Development Summit taking place in London from October 18<sup>th<\/sup> \u2013 20<sup>th<\/sup>. Dr. Nebot will be presenting on the development of shielding lipid novel excipients for LNP formulations at 11:00 AM local time, October 20<sup>th<\/sup>. His presentation will include insights on:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nStealth PEG alternative lipids with reduced immunogenicity\n<\/li>\n<li>\nCMC development of novel functional excipients\n<\/li>\n<li>\nSeamless LNP formulation development with alternative shielding lipids\n<\/li>\n<\/ul>\n<p>\n<b>About Curapath<\/b>\n<\/p>\n<p>\nCurapath is a leading GMP-grade manufacturer of polyamino-acid (PAA) and lipid-based nanoparticle encapsulation technology for advanced drug delivery applications including mRNA, DNA, cell therapies, gene therapies, biologics, vaccines, and small molecule therapies. The Curapath team of expert biochemists and polymeric material scientists are critical partners in the drug development and commercialization processes of some of the leading vaccine and therapeutics companies in the world. The company offers contract development and manufacturing services including preclinical development, analytical characterization, technology transfer, GMP manufacturing, and fill\/finish services. Learn more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.curapath.com&amp;esheet=52945034&amp;newsitemid=20221016005015&amp;lan=en-US&amp;anchor=www.curapath.com&amp;index=2&amp;md5=81218d8c0edbdef323aa06cd09992f61\" rel=\"nofollow noopener\" shape=\"rect\">www.curapath.com<\/a> and on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fpolypeptide-therapeutic-solutions%2F%3FviewAsMember%3Dtrue&amp;esheet=52945034&amp;newsitemid=20221016005015&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=a7e839ce9594d9f93dc4b0f4e8bb32b0\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p>\n<b>About Arcline Investment Management<\/b>\n<\/p>\n<p>\nArcline is a growth-oriented private equity firm with $4.4 billion in cumulative capital commitments. Arcline seeks to invest in technology-driven, meaningful to the world industrial businesses that enable a better future. For more information visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.arcline.com&amp;esheet=52945034&amp;newsitemid=20221016005015&amp;lan=en-US&amp;anchor=www.arcline.com&amp;index=4&amp;md5=698a068a034b5eb243747f1e33139f1a\" rel=\"nofollow noopener\" shape=\"rect\">www.arcline.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nChristine Quern<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#x3a;&#x63;&#113;&#x40;c&#104;&#x72;i&#115;&#x74;&#105;&#x6e;e&#113;&#x75;e&#114;&#x6e;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">c&#113;&#x40;&#x63;h&#114;&#x69;&#x73;t&#105;&#110;&#x65;&#x71;u&#101;&#x72;&#x6e;&#46;&#99;&#x6f;&#x6d;<\/a><br \/>617.650.8497\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned Company to present on shielding lipid novel excipients for lipid nanoparticle (LNP) formulations at Lipid Nanoparticles Development Summit on October 20th VALENCIA, Spain &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211;Polypeptide Therapeutic Solutions (PTS), a &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49668","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned Company to present on shielding lipid novel excipients for lipid nanoparticle (LNP) formulations at Lipid Nanoparticles Development Summit on October 20th VALENCIA, Spain &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211;Polypeptide Therapeutic Solutions (PTS), a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-17T06:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/21\/Curapath_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services\",\"datePublished\":\"2022-10-17T06:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/\"},\"wordCount\":567,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221016005015\\\/en\\\/1602434\\\/21\\\/Curapath_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/\",\"name\":\"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221016005015\\\/en\\\/1602434\\\/21\\\/Curapath_logo.jpg\",\"datePublished\":\"2022-10-17T06:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221016005015\\\/en\\\/1602434\\\/21\\\/Curapath_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221016005015\\\/en\\\/1602434\\\/21\\\/Curapath_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/","og_locale":"en_US","og_type":"article","og_title":"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services - Pharma Trend","og_description":"Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned Company to present on shielding lipid novel excipients for lipid nanoparticle (LNP) formulations at Lipid Nanoparticles Development Summit on October 20th VALENCIA, Spain &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211;Polypeptide Therapeutic Solutions (PTS), a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-17T06:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/21\/Curapath_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services","datePublished":"2022-10-17T06:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/"},"wordCount":567,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/21\/Curapath_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/","url":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/","name":"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/21\/Curapath_logo.jpg","datePublished":"2022-10-17T06:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/21\/Curapath_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221016005015\/en\/1602434\/21\/Curapath_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/polypeptide-therapeutic-solutions-pts-announces-company-name-change-to-curapath-and-expansion-of-drug-delivery-capabilities-and-services\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49668"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49668\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}